Normal view

Received — 10 September 2026 ⏭

Molecular Therapy
A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3 Dara Annett · Bethan J. Critchley · Kate L. Morling · Ben Graham · Valeria Pingitore · Thomas E. Whittaker · Nada Kurdi · Justin Warne · Shefta E. Moula · Diego León-Rico · Nihansu Kuru · Sara Toros · Tasnim Nurullah · Aura Hare · Matthew V.X. Whelan · A.W. Edith Chan · Richard S.B. Milne · Lydia S. Newton · Hashim Ali · Kate Powell · Matteo Rizzi · Adrian J. Thrasher · Lucy G. Thorne · David L. Selwood · Giorgia Santilli · Greg J. Towers
Cellular antiviral defenses limit lentivector gene delivery. The authors describe lentivector transduction enhancement via inhibition of antiviral IFITM3 by novel inhibitor BG147. BG147 has activity ex vivo in human stem cells and in vivo in mouse subretinal cells, driving IFITM3 degradation via lysosomes. BG147 can expand lentivector utility and reduce treatment costs.
3 August 2026 at 08:00

A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3

By: Dara Annett · Bethan J. Critchley · Kate L. Morling · Ben Graham · Valeria Pingitore · Thomas E. Whittaker · Nada Kurdi · Justin Warne · Shefta E. Moula · Diego León-Rico · Nihansu Kuru · Sara Toros · Tasnim Nurullah · Aura Hare · Matthew V.X. Whelan · A.W. Edith Chan · Richard S.B. Milne · Lydia S. Newton · Hashim Ali · Kate Powell · Matteo Rizzi · Adrian J. Thrasher · Lucy G. Thorne · David L. Selwood · Giorgia Santilli · Greg J. Towers

3 August 2026 at 08:00

Cellular antiviral defenses limit lentivector gene delivery. The authors describe lentivector transduction enhancement via inhibition of antiviral IFITM3 by novel inhibitor BG147. BG147 has activity ex vivo in human stem cells and in vivo in mouse subretinal cells, driving IFITM3 degradation via lysosomes. BG147 can expand lentivector utility and reduce treatment costs.